Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
about
Stress Response Leading to Resistance in Glioblastoma-The Need for Innovative Radiotherapy (iRT) ConceptsVaccine therapies in malignant gliomaEpidermal growth factor, from gene organization to bedsideImmunotherapy advances for glioblastomaTargeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastomaGuanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro.Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.Agile delivery of protein therapeutics to CNSCancer stem cells in glioblastomaNew therapeutic approaches for malignant glioma: in search of the Rosetta stonePretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.Trial watch: Peptide vaccines in cancer therapyChimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.microRNA-149 targets caspase-2 in glioma progression.Vaccine strategies for glioblastoma: progress and future directions.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma.Current Studies of Immunotherapy on GlioblastomaManagement of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.PDGFR-β-activated ACK1-AKT signaling promotes glioma tumorigenesis.Some Gram-negative Lipoproteins Keep Their Surface Topology When Transplanted from One Species to Another and Deliver Foreign Polypeptides to the Bacterial Surface.Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination TherapySynergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles.miR-137 acts as a tumor suppressor via inhibiting CXCL12 in human glioblastoma.FHL2 interacts with EGFR to promote glioblastoma growth.Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model.A Critical Overview of Targeted Therapies for GlioblastomaVaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models
P2860
Q26771706-17F020B5-A50F-4AFB-AC3A-1208C941CB29Q26829328-3DC5B916-C4B0-482F-B324-2832AED305BCQ26865616-939A8436-8F00-48B6-AEDB-50973F0061B3Q26866513-59E07E4D-C6B1-4C6C-81C0-9B832180F98CQ27022941-904BF1CC-E579-4892-9D38-99D4016C9B36Q30277399-9453EC00-FBAC-4F8E-AD1E-3BFE47759E04Q33795137-AAF4585E-4EE9-477F-AF96-C9BFB07EDE68Q33929529-FC404908-DADC-40CB-B1D9-CD37ABA6F5A6Q34079647-15727C0E-0A9D-4D30-BA42-FBC0AFBEB393Q35829972-A91AF118-A4D0-46F2-89B0-A0BAC378D0F0Q36224493-F3A70CDC-0F3F-470D-9A02-A4145DDDB10CQ36459981-FBF81942-EDD5-4BD5-948E-E91EAAE97A7FQ36476100-D0D46F5B-FE84-4A05-9FE0-CFA4FEB1AD3BQ36858767-127B7F5D-D0EE-4199-A3C2-1693CC943217Q37295673-679A7C79-D351-4827-BD29-5264FF39328DQ38081910-DFCD6455-1F64-4BC4-AB84-1635036EDD11Q38108186-F763D2EC-28DA-4C5F-BC49-E81DBA057CFCQ38172182-EF0B67D3-6BE8-428F-8CF5-0D115D96D179Q38176547-890592DE-F00F-4027-9219-08F8944CFCD5Q38262914-CC32DAD7-B8DB-4507-9918-682F9C438645Q38273428-F837CCA5-58F4-4EF5-9C35-D932DC12C12AQ38593312-C50817E5-96FD-4AF2-9650-17B1C85F04D4Q38603909-105E76C2-454D-46C9-ADBB-2C33722CBB2DQ38953165-F9E53936-B552-482E-9E2A-0E4800D19383Q40955783-3F8A5C35-86FF-46C3-9551-66EBEBB92AA3Q41485890-81E4A2D6-4781-4949-8C83-6B7C164D9FE2Q47095060-87EF819D-578A-4F7E-895C-F8B7716FC09CQ47149262-4EF45267-94DA-4B67-AD89-DD4BF96E0582Q47871595-E2982E92-324B-40BD-BB48-1CF9DCF44031Q55000389-247128F8-636E-4DC3-99AE-A151BA92045CQ58122179-621892B3-80C9-4312-91EB-DFF132D45DF9Q58707546-B18DA78F-0DF8-40B9-A749-3A667630A5A5
P2860
Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting EGF receptor variant ...... ination for malignant gliomas.
@en
Targeting EGF receptor variant ...... ination for malignant gliomas.
@nl
type
label
Targeting EGF receptor variant ...... ination for malignant gliomas.
@en
Targeting EGF receptor variant ...... ination for malignant gliomas.
@nl
prefLabel
Targeting EGF receptor variant ...... ination for malignant gliomas.
@en
Targeting EGF receptor variant ...... ination for malignant gliomas.
@nl
P2860
P356
P1476
Targeting EGF receptor variant ...... cination for malignant gliomas
@en
P2093
Albert J Wong
P2860
P304
P356
10.1586/ERV.11.177
P577
2012-02-01T00:00:00Z